Tumour Hypoxia: Impact on Biology, Prognosis and Treatment of Solid Malignant TumoursWeinmann M.a · Belka C.a · Plasswilm L.b
aKlinik für Radioonkologie, Universität Tübingen, Germany; bRadioonkologie, Universitätsklinik, Kantonsspital Basel, Switzerland
Tumour hypoxia is a major constraint for radiotherapy and many types of chemotherapy. A variety of different pathogenetic mechanisms contribute to the development of hypoxia in solid tumours. Hypoxia is associated with unfavourable prognosis, regardless of the treatment modality applied. Two different effects have been considered to explain the deleterious effects of hypoxia on the outcome of tumour patients. The first aspect encompasses the direct interference of hypoxia with antineoplastic treatment modalities. The efficacy of ionizing radiation, but also of a variety of cytotoxic drugs and cytokines rely directly on adequate oxygen tensions. The second aspect concerns the effects of hypoxia on the biology of tumour and stromal cells. Hypoxia is related to malignant progression, increased invasion, angiogenesis and an increased risk of metastasis formation. Possibly, hypoxia is furthermore a stressor which selects cells with increased resistance to apoptosis and thereby indirectly contributes to treatment resistance. This article reviews in brief the specific pathophysiology of tumour oxygenation and its implications for prognosis, tumour treatment and biology.
© 2004 S. Karger GmbH, Freiburg
Onkologie (International Journal for Cancer Research and Treatment)
Offizielles Organ von DGHO – Deutsche Gesellschaft für Hämatologie und Onkologie / ÖGHO – Österreichische Gesellschaft für Hämatologie und Onkologie / DFaG – Deutsche Fatigue Gesellschaft / AIO – Arbeitsgemeinschaft Internistische Onkologie in der deutschen Krebsgesellschaft e.V.
Vol. 27, No. 1, Year 2004 (Cover Date: February 2004)
Journal Editor: H.-J. Schmoll, Halle
ISSN: 0378–584X (print), 1423–0240 (Online)
For additional information: http://www.karger.com/onk